

CLAIMS

1. An isolated crystalline form of 2-methyl-1-[(4-[6- {(trifluoromethyl)pyridin-2-yl]-6- {[2-trifluoromethyl]pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 7.5, 9.3, 14.5, 18.8, 21.3, and $24.8^\circ \pm 0.2^\circ$.
2. The isolated crystalline form of claim 1, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 5.
3. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6- {[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 14.1, 19.1, 21.8, 23.5, and $25.7^\circ \pm 0.2^\circ$.
4. The isolated crystalline form of claim 3, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 15.
5. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl] -6- {[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 9.0, 9.2, 21.9, 22.1, 24.2, and $24.6^\circ \pm 0.2^\circ$.
6. The isolated crystalline form of claim 5, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 17.
7. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6- {[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.5, 19.6, 20. 1, and $21.6^\circ \pm 0.2^\circ$.
8. The isolated crystalline form of claim 7, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 19.
9. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6- {[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.5, 19.0, 19.4, 19.9, and $24.7^\circ \pm 0.2^\circ$.

10. The isolated crystalline form of claim 9, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 9.
11. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-trifluoromethyl) pyridin-4-yl] amino}-1,3,5-triazin-2-yl) amino] propan-2-ol methanesulfonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 7.1, 14.5, 17.1, and $21.8^\circ \pm 0.2^\circ$.
12. The isolated crystalline form of claim 11, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 11.
13. An isolated crystalline form of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.3, 7.2, 8.1, 12.7, and $14.9^\circ \pm 0.2^\circ$.
14. The isolated crystalline form of claim 13, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 13.
15. An isolated crystalline form of 2-methyl-1-[(4-[6- (trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl] amino}-1,3,5-triazin-2-yl) amino] propan-2-ol methanesufonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.7, 9.1, 10.8, 19.9, and $21.9^\circ \pm 0.2^\circ$.
16. The isolated crystalline form of claim 15, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 21.
17. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.3, 20.0, 20.2, 20.5, 21.2, and $26.5^\circ \pm 0.2^\circ$.
18. The isolated crystalline form of claim 17, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 23.
19. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6- {[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 7.2, 7.4, 8.0, 8.2, 16.5, and $18.6^\circ \pm 0.2^\circ$.

20. The isolated crystalline form of claim 19, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 26.
21. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6- {[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.3, 12.7, and $20.3^\circ \pm 0.2^\circ$.
22. The isolated crystalline form of claim 21, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 28.
23. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6- {[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.6, 17.5, 20.8 and $23.3^\circ \pm 0.2^\circ$.
24. The isolated crystalline form of claim 23, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 30.
25. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6- {[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, wherein the isolated crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.4, 12.9, 20.2, and $26.1^\circ \pm 0.2^\circ$.
26. The isolated crystalline form of claim 25, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 32.
27. Use of the crystalline form of any one of claims 1-26 in the manufacture of a medicament for treating an advanced hematologic malignancy in a subject, wherein the advanced hematologic malignancy selected from acute myelogenous leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2.
28. The use of claim 27, wherein the crystalline form is to be administered to the subject at a dose of 30 mg to 300 mg free-base equivalent strength, once daily or twice daily.
29. The use of claim 28, wherein the dose is about 75 mg, once daily or twice daily.
30. The use of claim 28, wherein the dose is about 100 mg, once daily or twice daily.

31. The use of claim 28, wherein the dose is about 150 mg, once daily or twice daily.
32. The use of claim 28, wherein the dose is about 200 mg, once daily or twice daily.
33. The use of any one of claims 27-32, wherein the crystalline form is to be administered as an oral dosage form.
34. The use of claim 33, wherein the oral dosage form is a tablet.
35. The use of claim 27, wherein the crystalline form is to be administered orally as any combination of 5, 10, 50, or 200 mg free-base equivalent strength tablets, twice daily or once daily.
36. The use of any one of claims 27-35, wherein the advanced hematologic malignancy is acute myelogenous leukemia.
37. The use of claim 36, wherein the acute myelogenous leukemia is relapsed or primary refractory acute myelogenous leukemia.
38. The use of any one of claims 27-35, wherein the advanced hematologic malignancy is myelodysplastic syndrome.
39. The use of any one of claims 27-35, wherein the advanced hematologic malignancy is chronic myelomonocytic leukemia.
40. The use of any one of claims 27-35, wherein the advanced hematologic malignancy is lymphoma.
41. The use of any one of claim 27-40, wherein the crystalline form is to be administered as a first line, second line, third line, or fourth line treatment for acute myelogenous leukemia.
42. A pharmaceutical composition comprising the crystalline form of any one of claims 1-26 and a pharmaceutically acceptable carrier.